CD4+/CD56+ hematodermic neoplasm
MONDO:0019467An aggressive immature hematologic neoplasm formerly known as blastic NK cell lymphoma, composed of cells with a lymphoblast-like morphology. Recent evidence suggests derivation from a plasmacytoid monocyte. Patients present with cutaneous tumors and bone marrow involvement.
Also known as: BPDCN, CD4+/CD56+ hematodermic neoplasm, agranular CD4+ CD56+ hematodermic neoplasm/tumor, agranular CD4+ natural Killer cell leukaemia, agranular CD4+ natural Killer cell leukemia, blastic NK-cell lymphoma, blastic natural Killer leukemia/lymphoma, blastic plasmacytoid Dendritic cell neoplasm
3160 clinical trials for this condition and its sub-types, 31 tagged with CD4+/CD56+ hematodermic neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Engineered immune cells take aim at Hard-to-Treat leukemias
Cure CompletedThis trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
New cord blood matching method could expand transplant access for blood cancer patients
Disease control CompletedThis study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental drug targets rare blood cancer in tiny trial
Disease control CompletedThis early-phase study tested the drug venetoclax in 5 adults with a rare blood cancer called BPDCN that had come back or not responded to prior treatment. The goal was to check safety and see if the drug could shrink tumors. Venetoclax works by helping cancer cells self-destruct…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New antibody drug tested in patients with relapsed blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC